Parallel Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $114K | Buy |
1,997
+229
| +13% | +$12.5K | ﹤0.01% | 1618 |
|
|
2026
Q1 | $99.9K | Buy |
1,768
+448
| +34% | +$26.1K | ﹤0.01% | 1591 |
|
|
2025
Q4 | $78.4K | Buy |
1,320
+551
| +72% | +$30K | ﹤0.01% | 1603 |
|
|
2025
Q3 | $41.6K | Buy |
769
+295
| +62% | +$16.9K | ﹤0.01% | 1881 |
|
|
2025
Q2 | $26K | Sell |
474
-861
| -64% | -$50.7K | ﹤0.01% | 2070 |
|
|
2025
Q1 | $94.4K | Buy |
1,335
+660
| +98% | +$44.4K | ﹤0.01% | 1301 |
|
|
2024
Q4 | $44.4K | Sell |
675
-395
| -37% | -$26.5K | ﹤0.01% | 1698 |
|
|
2024
Q3 | $75.2K | Sell |
1,070
-1,064
| -50% | -$88.9K | ﹤0.01% | 1405 |
|
|
2024
Q2 | $176K | Sell |
2,134
-233
| -10% | -$19.4K | ﹤0.01% | 923 |
|
|
2024
Q1 | $207K | Buy |
2,367
+169
| +8% | +$15.1K | 0.01% | 843 |
|
|
2023
Q4 | $212K | Sell |
2,198
-154
| -7% | -$13.6K | 0.01% | 772 |
|
|
2023
Q3 | $208K | Sell |
2,352
-3,062
| -57% | -$272K | 0.01% | 771 |
|
|
2023
Q2 | $469K | Sell |
5,414
-604
| -10% | -$56.8K | 0.02% | 486 |
|
|
2023
Q1 | $585K | Buy |
6,018
+1,046
| +21% | +$108K | 0.02% | 415 |
|
|
2022
Q4 | $515K | Buy |
4,972
+439
| +10% | +$41.2K | 0.02% | 399 |
|
|
2022
Q3 | $384K | Buy |
4,533
+3,289
| +264% | +$293K | 0.02% | 463 |
|
|
2022
Q2 | $103K | Buy |
1,244
+29
| +2% | +$2.31K | ﹤0.01% | 946 |
|
|
2022
Q1 | $95K | Sell |
1,215
-262
| -18% | -$21.9K | ﹤0.01% | 1007 |
|
|
2021
Q4 | $130K | Buy |
1,477
+750
| +103% | +$61.9K | ﹤0.01% | 904 |
|
|
2021
Q3 | $56K | Buy |
727
+32
| +5% | +$2.52K | ﹤0.01% | 1224 |
|
|
2021
Q2 | $58K | Buy |
695
+117
| +20% | +$9.28K | ﹤0.01% | 1179 |
|
|
2021
Q1 | $44K | Hold |
578
| – | – | ﹤0.01% | 1234 |
|
|
2020
Q4 | $51K | Sell |
578
-125
| -18% | -$9.91K | ﹤0.01% | 1084 |
|
|
2020
Q3 | $53K | Buy |
703
+221
| +46% | +$22.4K | ﹤0.01% | 1041 |
|
|
2020
Q2 | $59K | Buy |
482
+75
| +18% | +$7.45K | ﹤0.01% | 978 |
|
|
2020
Q1 | $34K | Buy |
407
+33
| +9% | +$2.84K | ﹤0.01% | 1077 |
|
|
2019
Q4 | $32K | Hold |
374
| – | – | ﹤0.01% | 1197 |
|
|
2019
Q3 | $25K | Buy |
374
+21
| +6% | +$1.62K | ﹤0.01% | 1253 |
|
|
2019
Q2 | $30K | Sell |
353
-65
| -16% | -$5.56K | ﹤0.01% | 1102 |
|
|
2019
Q1 | $37K | Sell |
418
-57
| -12% | -$5.28K | ﹤0.01% | 954 |
|
|
2018
Q4 | $40K | Sell |
475
-3,003
| -86% | -$286K | 0.01% | 831 |
|
|
2018
Q3 | $337K | Buy |
3,478
+500
| +17% | +$49.9K | 0.04% | 276 |
|
|
2018
Q2 | $280K | Buy |
2,978
+1,993
| +202% | +$175K | 0.04% | 276 |
|
|
2018
Q1 | $80K | Sell |
985
-51
| -5% | -$4.38K | 0.01% | 565 |
|
|
2017
Q4 | $92K | Buy |
1,036
+44
| +4% | +$3.83K | 0.02% | 509 |
|
|
2017
Q3 | $80K | Sell |
992
-36
| -4% | -$3.18K | 0.01% | 536 |
|
|
2017
Q2 | $90K | Sell |
1,028
-14
| -1% | -$1.27K | 0.02% | 502 |
|
|
2017
Q1 | $100K | Buy |
1,042
+125
| +14% | +$11.1K | 0.02% | 441 |
|
|
2016
Q4 | $76K | Buy |
+917
| New | +$78.9K | 0.02% | 455 |
|
Other funds holding BMRN
VPC
Parallel Advisors's BMRN Position: Q2 2026 in Review
Parallel Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 13% in Q2 2026, buying an estimated $12.5K and bringing the position to 1,997 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #1618.
Parallel Advisors first reported a position in BMRN in Q4 2016 and has held it in 39 quarters since. The position peaked at $585K in Q1 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Parallel Advisors held 1,997 shares of BioMarin Pharmaceuticals worth $114K as of Q2 2026.
- Parallel Advisors bought 229 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $12.5K.
- BioMarin Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1618 holding.
- Parallel Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
- Parallel Advisors's BioMarin Pharmaceuticals position peaked at $585K in Q1 2023.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.